Abstract
The hypoxia-inducible factor HIF-1 has been shown to be mandatory for the cellular adaptation to hypoxia. In addition, evidence has been provided that HIF-1 can mediate various stress responses and that it may play an important role under inflammatory conditions even independently of hypoxia. HIF-1 is a heterodimer consisting of an α-subunit which is subject to tight regulation, and a β-subunit, also termed ARNT, which appears to be constitutively expressed. In addition to the complex network controlling the cellular content of HIF-1α at the level of protein stability, recent evidence showed that HIF-1α levels can also be regulated at the mRNA level. In fact, transcriptional regulatory networks seem to be an additional way of controlling HIF-1α levels and may open new therapeutic options to modulate HIF-1α also under non-hypoxic conditions.
Keywords: HIF, nuclear factor kappa b, transcription, promoter, reactive oxygen species, hypoxia
Current Pharmaceutical Design
Title: Regulation of HIF-1α at the Transcriptional Level
Volume: 15 Issue: 33
Author(s): Agnes Gorlach
Affiliation:
Keywords: HIF, nuclear factor kappa b, transcription, promoter, reactive oxygen species, hypoxia
Abstract: The hypoxia-inducible factor HIF-1 has been shown to be mandatory for the cellular adaptation to hypoxia. In addition, evidence has been provided that HIF-1 can mediate various stress responses and that it may play an important role under inflammatory conditions even independently of hypoxia. HIF-1 is a heterodimer consisting of an α-subunit which is subject to tight regulation, and a β-subunit, also termed ARNT, which appears to be constitutively expressed. In addition to the complex network controlling the cellular content of HIF-1α at the level of protein stability, recent evidence showed that HIF-1α levels can also be regulated at the mRNA level. In fact, transcriptional regulatory networks seem to be an additional way of controlling HIF-1α levels and may open new therapeutic options to modulate HIF-1α also under non-hypoxic conditions.
Export Options
About this article
Cite this article as:
Gorlach Agnes, Regulation of HIF-1α at the Transcriptional Level, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649420
DOI https://dx.doi.org/10.2174/138161209789649420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets LC-MS/MS Method Development and Validation for the Determination of Ilexsaponin A1 and Its Application in Intestinal Bacterial Metabolic Study
Current Pharmaceutical Analysis Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Mononuclear Cell Recruitment and Inflammation in Atherosclerosis
Vascular Disease Prevention (Discontinued) Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design The Protective Roles and Molecular Mechanisms of Troxerutin (Vitamin P4) for the Treatment of Chronic Diseases: A Mechanistic Review
Current Neuropharmacology Editorial
Current Medical Imaging Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Cardiac Applications for Human Pluripotent Stem Cells
Current Pharmaceutical Design Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design Tombstoning ST-Elevation Myocardial Infarction
Current Cardiology Reviews Good at Heart: Preserving Cardiac Metabolism during aging
Current Diabetes Reviews